MeiraGTx Holdings, a clinical-stage genetic medicines company, has entered a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. Per the agreement, MeiraGTx will receive $200 million in upfront cash at closing, and MeiraGTx and Hologen are forming a joint venture, called Hologen Neuro AI Ltd. MeiraGTx will retain 30% ownership in the Hologen Neuro A...